154 research outputs found
Topoisomer Differentiation of Molecular Knots by FTICR MS: Lessons from Class II Lasso Peptides
Lasso peptides constitute a class of bioactive peptides sharing a knotted
structure where the C-terminal tail of the peptide is threaded through and
trapped within an N-terminalmacrolactamring. The structural characterization of
lasso structures and differentiation from their unthreaded topoisomers is not
trivial and generally requires the use of complementary biochemical and
spectroscopic methods. Here we investigated two antimicrobial peptides
belonging to the class II lasso peptide family and their corresponding
unthreaded topoisomers: microcin J25 (MccJ25), which is known to yield
two-peptide product ions specific of the lasso structure under collisioninduced
dissociation (CID), and capistruin, for which CID does not permit to
unambiguously assign the lasso structure. The two pairs of topoisomers were
analyzed by electrospray ionization Fourier transform ion cyclotron resonance
mass spectrometry (ESI-FTICR MS) upon CID, infrared multiple photon
dissociation (IRMPD), and electron capture dissociation (ECD). CID and
ECDspectra clearly permitted to differentiate MccJ25 from its non-lasso
topoisomer MccJ25-Icm, while for capistruin, only ECD was informative and
showed different extent of hydrogen migration (formation of c\bullet/z from
c/z\bullet) for the threaded and unthreaded topoisomers. The ECD spectra of the
triply-charged MccJ25 and MccJ25-lcm showed a series of radical b-type product
ions {\eth}b0In{\TH}. We proposed that these ions are specific of
cyclic-branched peptides and result from a dual c/z\bullet and y/b
dissociation, in the ring and in the tail, respectively. This work shows the
potentiality of ECD for structural characterization of peptide topoisomers, as
well as the effect of conformation on hydrogen migration subsequent to electron
capture
Collateral Quality and Loan Default Risk: The Case of Vietnam
In the transition economy of Vietnam, financial market is dominated by banking sector but commercial banks heavily rely on collateral-based lending. While the relationship between collateral and implied credit risk is still in debate, this paper provides additional empirical evidence regarding the heterogeneous effects and transmission channels of collateral characteristics on loan delinquency. Applying instrumental variable probit analysis on a unique dataset of 2295 internal loan accounts in Vietnam, we find the significantly negative impact of collateral quality on the probability of default of consumer loans, supporting the dominance of borrower selection and risk-shifting over lender selection effects. The finding implies that high-quality collateral not only signals more credible borrower but also fosters good behavior in using loan, enabling bank to mitigate adverse selection and moral hazard problems
Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518)
BACKGROUND: Even today, treatment of Stage III NSCLC still poses a serious challenge. So far, surgical resection is the treatment of choice. Patients whose tumour is not resectable or who are unfit to undergo surgery are usually referred to a combined radio-chemotherapy. However, combined radio-chemotherapeutic treatment is also associated with sometimes marked side effects but has been shown to be more efficient than radiation therapy alone. Nevertheless, there is a significant subset of patients whose overall condition does not permit administration of chemotherapy in a combined-modality treatment. It could be demonstrated though, that NSCLCs often exhibit over-expression of EGF-receptors hence providing an excellent target for the monoclonal EGFR-antagonist cetuximab (Erbitux(®)) which has already been shown to be effective in colorectal as well as head-and-neck tumours with comparatively mild side-effects. METHODS/DESIGN: The NEAR trial is a prospective phase II feasibility study combining a monoclonal EGF-receptor antibody with loco-regional irradiation in patients with stage III NSCLC. This trial aims at testing the combination's efficacy and rate of development of distant metastases with an accrual of 30 patients. Patients receive weekly infusions of cetuximab (Erbitux(®)) plus loco-regional radiation therapy as intensity-modulated radiation therapy. After conclusion of radiation treatment patients continue to receive weekly cetuximab for 13 more cycles. DISCUSSION: The primary objective of the NEAR trial is to evaluate toxicities and feasibility of the combined treatment with cetuximab (Erbitux(®)) and IMRT loco-regional irradiation. Secondary objectives are remission rates, 3-year-survival and local/systemic progression-free survival
- …